Today’s AI Top Pick: AHCO
8/13/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.
AI-ranked from a screened shortlist, with entry strategy, targets, and risks.
View the live AHCO price forecast →
AHCO (AdaptHealth) is the cleanest contrarian bounce setup in this pool. All three timeframes point up with meaningful magnitude: 4h forecasts +72.36/+76.21/+74.95%, 1d +48.00/+74.73/+71.36%, and even the 1wk (usually the laggard on beaten-down names) is +19.94/+44.96/+57.26%. That is rare — most other candidates have at least one timeframe going the wrong way (LZ 1wk short -7.49, PLTK 4h long +41 but 1d/1wk mixed, APP 1wk fc_long -73.12, CHGG 1wk -64.14). Bullish probability is 1.0, near_term_bullish is 1.0, and the drawdown of -45.98% has stopped making fresh lows — 4h pos_in_21bar_range is 5.32%, 1d 10.50%, so we are buying near the floor, not chasing. The fundamental picture is not glamorous (fund_score 1.5, profitMargin -7.05%, debtEq 1.5) but it is fixable rather than broken: salesYoY basically flat at -0.43%, epsNextY +86.75%, ps only 0.24, and analyst recom 1.14 with targetUpsidePct +58.4%. Crucially, the news flow is a positive catalyst rather than a landmine — a director just purchased ~$150k of stock on Aug 11 following the Q2 call. Insider buying immediately after earnings, into a -46% drawdown, is exactly the tell you want that the print was digestible and management sees value here. Compare that with the top-fundamentals name (OPFI, score 8) which just got hit with 'analysts cut forecasts on weak Q2' and a fair-value cut — a textbook 'strong forecast undercut by bad headline' pass. Timing: RSI 23.5 is deeply oversold; the 4h and 1d bars have stabilized (recent_21bar_pct on 4h is -43.8 but current sits only 5% off that low with the forecast reversing up); and the 1wk forecast being positive across all three horizons means the model does not see this as a broken trend. Every other setup with comparable forecast magnitude has a hair on it — SNAL missed revenue and dropped 31% AH, MYGN cut guidance, CMRC cut guidance, BETR lost its CEO, PACB got a 'only getting worse' note, CNTX dropped a pipeline asset. AHCO is the only name where the strong quantitative setup is paired with a fresh, tangible positive catalyst (director open-market buy) rather than a negative one. Why today, not later: pos_in_21bar_range at 5-10% means we are at, not above, the bounce zone; waiting risks buying after the first 15-20% snap-back that the fc_short of +48% (1d) implies. Stop is well-defined just under the recent low ($5.20 area), giving a favorable ~1:3+ reward-to-risk against the mid-term target.
- Balance-sheet risk: debtEq 1.50 with profitMargin -7.05% and grossMargin only 15.94% — a rate scare or reimbursement cut could re-accelerate the downtrend
- Healthcare/DME reimbursement headline risk (CMS policy or payer changes) could invalidate the bounce fast on a name already down 42% YTD
- 1wk fc_short of only +19.94% vs. 4h/1d +48-72% means the weekly chart still lags — a broader tape sell-off could pull it back to the $5.15-5.20 stop before the bounce triggers
- shortFloat 9.33% is elevated; if the reclaim fails, forced longs unwinding can amplify downside
- salesYoY -0.43% and marketCap only $787M — a small-cap with no growth cushion; any Q3 pre-announcement miss would hit hard
| # | Symbol | Verdict | Score | Read |
|---|---|---|---|---|
| 1 | AHCO | BUY NOW | 8.6 | All-TF bullish forecasts (+48–76%), floor of the range, insider director buy $150k post-earnings — cleanest catalyst-backed bounce in the pool. |
| 2 | LZ | BUY NOW | 8.1 | Cheapest quality name (fwdPe 6.57, peg 0.54) with positive Q2 narrative and 4h/1d forecasts +19/+37/+58. |
| 3 | PLTK | BUY NOW | 7.6 | Reaffirmed guidance + 42% undervalued call, 1wk fc_long +101%, floor-hugging pos_in_range 0.07%. |
| 4 | NABL | BUY NOW | 7.2 | Explicit 'contrarian buy after Q2 selloff' thesis with 1wk fc_mid/long +165/+183% — RBC downgrade a minor offset. |
| 5 | BAER | BUY NOW | 6.8 | All TFs strongly bullish (4h fc_long +77%), Super Scooper contract expansion is a real catalyst; micro-cap risk keeps size small. |
| 6 | MNST | BUY PULLBACK | 6.4 | 1d fc +59.61 mid but 1h pos_in_range already 89% — already bounced hard, wait for a pullback. |
| 7 | USNA | BUY PULLBACK | 6.2 | Strong daily fc +31/+58/+65 but 1h pos_in_range 68% shows early bounce is in — chase risk. |
| 8 | TRIP | BUY PULLBACK | 6.0 | Airbnb partnership is a genuine positive catalyst; 1wk fc_long +62.83% but 4h forecasts modest (+11/+1/+16). |
| 9 | ARDX | BUY PULLBACK | 5.7 | Raised IBSRELA guidance is positive, RSI 19.5 oversold, but 'payer friction' overhang and 1wk fc_short only +8%. |
| 10 | INDP | WAIT | 5.3 | Weekly forecasts absurd (+784/+860/+1183%) but micro-cap ($115M) biotech at $1.06 — lottery ticket, not a portfolio buy. |
| 11 | APP | WAIT | 5.0 | Best fundamentals (score 8) but 'plunged to 52-week low' headline + 1wk fc_long -73.12% is a huge red flag. |
| 12 | LCX-USD | WAIT | 4.9 | Only 1d TF available with modest +21% forecast — not enough signal edge. |
| 13 | WEAV | WAIT | 4.7 | 4h fc_long only +2.88% shows model losing conviction on longest 4h horizon; near_term_bullish only 0.4. |
| 14 | CNTX | WAIT | 4.5 | Dropped bispecific T-cell engager for cost cutting — pipeline attrition news undercuts the extreme +348% 4h forecast. |
| 15 | SNAL | WAIT | 4.3 | Missed Q2 revenue and dropped 31% AH; 1d fc_long -71.72% contradicts the 4h bounce signal. |
| 16 | TYGO | WAIT | 4.1 | 4h fc_short +164% is spicy but only 2 TFs available and epsNextY -72.73% is grim. |
| 17 | OXT-USD | WAIT | 4.0 | 1d fc_short -3.25% says even the model doesn't see the bounce this week. |
| 18 | UAA | WAIT | 3.9 | CFO buy is a nice tell but Barclays downgrade citing market share losses + tariff pressures overwhelms modest +7/+5% 4h forecasts. |
| 19 | BROS | WAIT | 3.7 | 'Don't buy the dip, still too expensive' is the analyst take, 1wk fc_long -19% agrees. |
| 20 | ARKO | WAIT | 3.5 | Weak earnings + 'consumer sentiment at historic lows' framing, 4h fc modest +24-33%. |
| 21 | ALHC | WAIT | 3.4 | Lawsuit-driven accounting questions is a landmine; 1wk forecasts all negative (-3/-9/-9). |
| 22 | UTI | WAIT | 3.2 | 1d fc_short -0.2% and 1wk forecasts all negative — bounce thesis weak across horizons. |
| 23 | OPFI | AVOID | 3.0 | Fund score 8 undone by fresh analyst cuts on weak Q2 and 1wk forecasts all NEGATIVE (-0.07/-6.85/-7.85). |
| 24 | BETR | AVOID | 2.8 | CEO exit + shortFloat 35.7% + debtEq 11.36 — the +89% weekly forecast can't offset a governance shock. |
| 25 | CMRC | AVOID | 2.6 | Cut 2026 revenue outlook + Barclays underweight — recent guide-down invalidates the setup. |
| 26 | XPOF | AVOID | 2.4 | 'Execution and Guidance Under Pressure' after Q2, 1d fc_short only +0.93% — model agrees it's not ready. |
| 27 | CHGG | AVOID | 2.1 | 1wk fc_short/mid/long all -64.14% — the model outright rejects a weekly bounce. |
| 28 | MYGN | AVOID | 1.9 | Cut 2026 revenue outlook, Wells Fargo cut PT — freshly broken trend, not an exhausted one. |
| 29 | SPPL | AVOID | 1.6 | 1wk fc_short -37.35%, fund_score -1.5, profitMargin -71%, no analyst coverage — no thesis to buy. |
| 30 | PACB | AVOID | 1.2 | 'It's only getting worse' + fund score -2.75, operMargin -101.67% — this is a falling knife, not a bounce. |
Get AI top picks & forecasts on any stock
K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord